E. De-wit, N. Van-doremalen, D. Falzarano, and V. J. Munster, SARS and MERS: recent insights into emerging coronaviruses, Nat. Rev. Microbiol, vol.14, pp.523-534, 2016.

Q. Li, Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia, N. Engl. J. Med, vol.382, pp.1199-1207, 2020.

E. Callaway, D. Cyranoski, S. Mallapaty, E. Stoye, and J. Tollefson, The coronavirus pandemic in five powerful charts, Nature, 2020.

G. Li and E. De-clercq, Therapeutic options for the 2019 novel coronavirus (2019-nCoV), Nat. Rev. Drug Discov, vol.19, pp.149-150, 2020.

Y. Cheng, P. R. Williamson, and W. Zheng, Improving therapy of severe infections through drug repurposing of synergistic combinations, Curr. Opin. Pharmacol, vol.48, pp.92-98, 2019.

R. Manganaro, Synthesis and antiviral effect of novel fluoxetine analogues as enterovirus 2C inhibitors, Antiviral Res, vol.178, p.104781, 2020.

A. H. De-wilde, Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture, Antimicrob. Agents Chemother, vol.58, pp.4875-4884, 2014.

J. Dyall, Repurposing of clinically developed drugs for treatment of middle east respiratory syndrome coronavirus infection, Antimicrob. Agents Chemother, vol.58, pp.4885-4893, 2014.

B. Mercorelli, G. Palù, and A. Loregian, Drug repurposing for viral infectious diseases: how far are we?, Trends Microbiol, vol.26, pp.865-876, 2018.

L. Delang, The viral capping enzyme nsP1: a novel target for the inhibition of chikungunya virus infection, Sci. Rep, vol.6, p.31819, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01439113

F. Touret, Phylogenetically based establishment of a dengue virus panel, representing all available genotypes, as a tool in dengue drug discovery, Antiviral Res, vol.168, pp.109-113, 2019.
URL : https://hal.archives-ouvertes.fr/hal-02617069

J. Blaising, S. J. Polyak, and E. Pécheur, Arbidol as a broad-spectrum antiviral: an update, Antiviral Res, vol.107, pp.84-94, 2014.

J. Liu, Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro, Cell Discov, vol.6, p.16, 2020.

, (1234567890) Scientific RepoRtS | (2020) 10:13093 |

M. Wang, Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro, Cell Res, vol.1, pp.1-3, 2020.

X. Yao, In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Clin. Infect. Dis, 2020.

, Hydroxychloroquine to Prevent Covid19 Pneumonia (ALBERTA HOPE-Covid19), ClinicalTrials.gov, p.1, 2020.

, Efficacy and safety of darunavir and cobicistat for treatment of pneumonia caused by 2019-nCoV, ClinicalTrials.gov, p.45, 2020.

, Azithromycin for Hospitalized Patients with Suspected or Confirmed COVID-19, ClinicalTrials.gov, 2020.

, Lack of Antiviral Activity of Darunavir against SARS-CoV-2, 2020.

G. M. Kuster, SARS-CoV2: should inhibitors of the renin-angiotensin system be withdrawn in patients with COVID-19?, Eur. Heart J, p.235, 2020.

J. Lan, Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor, Nature, 2020.

, Treatments to Decrease the Risk of Hospitalization or Death in Elderly Outpatients With Symptomatic SARS-CoV-2 Infection (COVID-19), ClinicalTrials.gov, 2020.

, Preliminary estimates of the prevalence of selected underlying health conditions among patients with coronavirus disease 2019-United States, MMWR Morb. Mortal. Wkly. Rep, vol.69, 2020.

M. Miyara, Low incidence of daily active tobacco smoking in patients with symptomatic COVID-19, Qeios, 2020.

W. Guan, Clinical characteristics of coronavirus disease 2019 in China, N. Engl. J. Med, vol.382, pp.1708-1720, 2020.

J. M. Oakes, R. M. Fuchs, J. D. Gardner, E. Lazartigues, and X. Yue, Nicotine and the renin-angiotensin system, Am. J. Physiol. Regul. Integr. Comp. Physiol, vol.315, pp.895-906, 2018.

D. H. Tran, Azithromycin, a 15-membered macrolide antibiotic, inhibits influenza A(H1N1)pdm09 virus infection by interfering with virus internalization process, J. Antibiot. (Tokyo), vol.72, pp.759-768, 2019.

E. C. Goodwin, W. J. Atwood, and D. Dimaio, High-throughput cell-based screen for chemicals that inhibit infection by simian virus 40 and human polyomaviruses, J. Virol, vol.83, pp.5630-5639, 2009.

P. Dahlem, W. M. Van-aalderen, M. De-neef, M. G. Dijkgraaf, and A. P. Bos, Randomized controlled trial of aerosolized prostacyclin therapy in children with acute lung injury, Crit Care Med, vol.32, pp.1055-1060, 2004.

N. Mumtaz, Cell-line dependent antiviral activity of sofosbuvir against Zika virus, Antiviral Res, vol.146, pp.161-163, 2017.

P. Maisonnasse, Hydroxychloroquine in the treatment and prophylaxis of SARS-CoV-2 infection in non-human primates, 2020.

S. Weston, Broad anti-coronaviral activity of FDA approved drugs against SARS-CoV-2 in vitro and SARS-CoV in vivo, 2020.

J. Haviernik, Arbidol (Umifenovir): a broad-spectrum antiviral drug that inhibits medically important arthropod-borne flaviviruses, Viruses, vol.10, p.184, 2018.